Ecor1 Capital, Llc Buys 39,029 Shares of Zymeworks Inc. (NYSE:ZYME) Stock

Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 39,029 shares of the stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average price of $14.01 per share, with a total value of $546,796.29. Following the purchase, the director now owns 15,578,732 shares in the company, valued at $218,258,035.32. This trade represents a 0.25 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, January 13th, Ecor1 Capital, Llc purchased 74,125 shares of Zymeworks stock. The shares were acquired at an average cost of $13.39 per share, with a total value of $992,533.75.
• On Friday, January 10th, Ecor1 Capital, Llc bought 204,098 shares of Zymeworks stock. The shares were acquired at an average cost of $13.13 per share, with a total value of $2,679,806.74.
• On Wednesday, January 8th, Ecor1 Capital, Llc purchased 21,021 shares of Zymeworks stock. The stock was bought at an average cost of $14.07 per share, for a total transaction of $295,765.47.
• On Thursday, January 2nd, Ecor1 Capital, Llc bought 157,880 shares of Zymeworks stock. The stock was acquired at an average cost of $14.78 per share, with a total value of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc purchased 58,988 shares of Zymeworks stock. The shares were purchased at an average price of $14.47 per share, with a total value of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc bought 11,958 shares of Zymeworks stock. The shares were purchased at an average price of $14.12 per share, for a total transaction of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc purchased 16,692 shares of Zymeworks stock. The stock was bought at an average price of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Stock Performance

Zymeworks stock traded up $0.42 during trading hours on Wednesday, hitting $14.04. The company had a trading volume of 383,497 shares, compared to its average volume of 564,289. The firm has a market cap of $967.05 million, a P/E ratio of -9.36 and a beta of 1.10. The company has a 50-day moving average price of $14.45 and a two-hundred day moving average price of $12.55. Zymeworks Inc. has a 1 year low of $7.97 and a 1 year high of $17.70.

Zymeworks (NYSE:ZYME - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.01. The firm had revenue of $16.00 million during the quarter, compared to analyst estimates of $17.90 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. Zymeworks's quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.41) earnings per share. As a group, equities research analysts anticipate that Zymeworks Inc. will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

ZYME has been the topic of a number of recent research reports. Citigroup upped their price target on shares of Zymeworks from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Monday, November 4th. JPMorgan Chase & Co. raised shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price target for the company in a report on Monday, December 16th. HC Wainwright reissued a "neutral" rating and set a $12.00 price objective on shares of Zymeworks in a research note on Friday, November 22nd. Leerink Partnrs raised Zymeworks from a "hold" rating to a "strong-buy" rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company lifted their price objective on shares of Zymeworks from $12.00 to $14.00 and gave the stock an "equal weight" rating in a research note on Thursday, December 19th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $19.17.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZYME. FMR LLC lifted its position in shares of Zymeworks by 84.2% in the 3rd quarter. FMR LLC now owns 3,336 shares of the company's stock worth $42,000 after purchasing an additional 1,525 shares during the period. DekaBank Deutsche Girozentrale bought a new position in Zymeworks in the third quarter worth approximately $47,000. Quest Partners LLC lifted its holdings in Zymeworks by 8,049.6% during the second quarter. Quest Partners LLC now owns 9,209 shares of the company's stock worth $78,000 after buying an additional 9,096 shares during the period. nVerses Capital LLC bought a new stake in Zymeworks during the 3rd quarter valued at $79,000. Finally, MQS Management LLC purchased a new position in shares of Zymeworks in the 2nd quarter valued at $92,000. 92.89% of the stock is currently owned by institutional investors.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.